ClinicalTrials.gg
CompletedNCT06732882Updated Jun 5, 2025

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.

A Phase 1 interventional study of AZD4604 and Placebo in Asthma, sponsored by AstraZeneca. Completed at 10 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
209th of 248
28 · median 175
Started
2025
with 12 others
Phase 1
46 of 359
none open now
Registered
337th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 209th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2025, is one of 46 in phase 1, and was the 337th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The study will investigate the Pharmacokinetic (PK), Pharmacodynamic (PD), the safety and tolerability of AZD4604, as well as to examine the effect of Fractional exhaled Nitric Oxide (FeNO) following the administration of the multiple doses of AZD4604 via Turbuhaler device.

Read the detailed description

This is a multicentre, randomised, placebo-controlled, single-blind study to characterise PK and PD of AZD4604, administered twice daily (BID) using a Turbuhaler or a Genuair device.

Participants who have mild asthma with a raised FeNO will be randomised into the study to evaluate AZD4604 versus placebo, at 2 dose levels delivered via: a) the Turbuhaler device and b) the Genuair device.

The study will be comprised of:

  • A screening period (Day -42 to Day-3)
  • Participants will be randomised to one of 5 treatment arms where participants will either receive BID doses of AZD4604 or placebo from Day 1 to Day 9 and a single dose on Day 10.
  • A follow-up Visit on Day 16

The total duration of the study will be for 58 days.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Turbuhaler device
  • Genuair device
  • Janus Kinase 1 inhibitor
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Participant must be 18 to 65 years of age inclusive with suitable veins for cannulation or repeated venepuncture.
  • Participants must have Physician-diagnosed mild asthma for at least 6 months prior to Screening Visit.
  • ≥ 70% predicted for at the Screening Visit AND on Day -1.
  • Have a FeNO of ≥ 40 ppb at the Screening Visit and on Day -2.
  • Body weight at least 50 kg and within the range 18 to 35 kg/m2 (inclusive).
  • Female participants must have a negative pregnancy test at the Screening Visit and on admission to the clinical site or prior to randomisation and must not be lactating. However, there are no restrictions on male participants or their female partners.
  • use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed and dated prior to any study-specific procedure.

Main Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Principal Investigator (PI), may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • History of cancer within the last 10 years (20 years for breast cancer) except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured. Any history of lymphoma is not allowed and disease history suggesting abnormal immune function.
  • Participants with increased risk of infection.
  • Have received any vaccine in the 30 days prior to the first dose.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of the study intervention.
  • History of serious or severe adverse reaction or known to AZD4604 or any of its additive constituents
  • High sensitivity C-reactive protein > (ULN) at Screening Visit and Baseline/Run-in Period.
  • Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results as judged by the PI. The PI may consider appropriate ethnicity adjusted local reference ranges for haematology or clinical chemistry measurements, when available.
  • Known or suspected history of drug abuse as judged by the PI and current smokers.
  • History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4604.
  • Use of drugs with enzyme-inducing properties such as St John's wort within 3 weeks prior to the first administration of study intervention.
  • History of alcohol abuse or excessive intake of alcohol as judged by the PI.
  • Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
  • Participants who cannot communicate reliably with the PI or vulnerable participants.
  • Any clinically important abnormalities in rhythm, conduction or morphology of the resting (ECG) and any clinically important abnormalities in the 12-lead ECG as considered by the investigator that may interfere with the interpretation of changes.
  • Female participants who are planning a pregnancy during the study period or within one month after the last dose of study intervention.
  • Exacerbation of asthma symptoms within 6 months prior to Screening Visit and Day -1 requiring the use of oral, IM or IV , antibiotics, accident and emergency visit, or hospital admission.
  • If in the judgement of the PI, the participant has any ongoing or recent (ie, during the Screening Period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements, the participant should not be enrolled.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of study intervention in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    AZD4604 dose A via Genuair

    Participants will receive dose A of AZD4604 via Genuair device twice daily

    Drug: AZD4604 · Device: Genuair

  • Experimental
    AZD4604 dose A via Turbuhaler

    Participants will receive dose A of AZD4604 via Turbuhaler device twice daily

    Drug: AZD4604 · Device: Turbuhaler

  • Experimental
    AZD4604 dose B via Turbuhaler

    Participants will receive dose B of AZD4604 via Turbuhaler device twice daily

    Drug: AZD4604 · Device: Turbuhaler

  • Placebo comparator
    Placebo via Genuair

    Participants will receive placebo via Genuair device twice daily

    Other: Placebo · Device: Genuair

  • Placebo comparator
    Placebo via Turbuhaler

    Participants will receive placebo via Turbuhaler device twice daily

    Other: Placebo · Device: Turbuhaler

Interventions

  • Participants will receive AZD4604 via Genuair/Turbuhaler device.

  • OtherPlacebo

    Participants will receive placebo via Genuair/Turbuhaler device.

  • DeviceGenuair

    Participants will either receive AZD4604 or placebo via Genuair device.

  • DeviceTurbuhaler

    Participants will receive either AZD4604 or placebo via Turbuhaler device.

06

What researchers measure

Primary outcomes

  1. Maximum observed drug concentration (Cmax) of AZD4604

    The Cmax of AZD4604 at Day 10 of dosing with dose A and dose B when delivered by the Turbuhaler device will be characterised.

    Time frame: Day 9 (Pre-dose) and Day 10 (Pre-dose and Post-dose)

  2. Time to reach maximum observed concentration (tmax) of AZD4604

    The tmax of AZD4604 at Day 10 of dosing with dose A and dose B when delivered by the Turbuhaler device will be characterised.

    Time frame: Day 9 (Pre-dose) and Day 10 (Pre-dose and Post-dose)

  3. Area under concentration-time curve in the dosing interval (AUCtau) of AZD4604

    The AUCtau of AZD4604 at Day 10 of dosing with dose A and dose B when delivered by the Turbuhaler device will be characterised.

    Time frame: Day 9 (Pre-dose) and Day 10 (Pre-dose and Post-dose)

  4. Apparent total body clearance (CL/F) of AZD4604

    The CL/F of AZD4604 at Day 10 of dosing with dose A and dose B when delivered by the Turbuhaler device will be characterised.

    Time frame: Day 10 (Pre-dose and Post-dose)

  5. Apparent volume of distribution based on the terminal phase (VZ/F) of AZD4604

    The VZ/F of AZD4604 at Day 10 of dosing with dose A and dose B when delivered by the Turbuhaler device will be characterised.

    Time frame: Day 10 (Pre-dose and Post-dose)

  6. Dose normalised AUCtau (AUCtau/D) of AZD4604

    The AUCtau/D of AZD4604 at Day 10 of dosing with dose A and dose B when delivered by the Turbuhaler device will be characterised.

    Time frame: Day 9 (Pre-dose) and Day 10 (Pre-dose and Post-dose)

  7. Dose normalised Cmax (Cmax/D) of AZD4604

    The Cmax/D of AZD4604 at Day 10 of dosing with dose A and dose B when delivered by the Turbuhaler device will be characterised.

    Time frame: Day 9 (Pre-dose) and Day 10 (Pre-dose and Post-dose)

Secondary outcomes

  1. Change from baseline to end of treatment in FeNO levels

    The change in FeNO levels from baseline to end of treatment after administration of AZD4604 delivered via Turbuhaler device will be evaluated.

    Time frame: From Screening visit (Day -42 to Day -3), Day -2 to Day 4, Day 9 to Day 10, Follow-up visit (Day 16)

  2. Percentage of participants who achieve a FeNO < 25 ppb Cmax/D

    The percentage of participants who achieve a FeNO \<25 ppb after administration of AZD4604 delivered via Turbuhaler device will be evaluated.

    Time frame: From Screening visit (Day -42 to Day -3), Day -2 to Day 4, Day 9 to Day 10, Follow-up visit (Day 16)

  3. Change from baseline to end of treatment in FeNO levels

    The change in FeNO levels from baseline to end of treatment after administration of AZD4604 delivered via Turbuhaler and Genuair devices will be evaluated.

    Time frame: From Screening visit (Day -42 to Day -3), Day -2 to Day 4, Day 9 to Day 10, Follow-up visit (Day 16)

  4. Maximum observed drug concentration (Cmax) of AZD4604

    The Cmax of AZD4604 at Day 10 of dosing with dose A, when delivered by the Genuair device will be characterised.

    Time frame: Day 9 and Day 10

  5. Time to reach maximum observed concentration (tmax) of AZD4604

    The tmax of AZD4604 at Day 10 of dosing with dose A, when delivered by the Genuair device will be characterised.

    Time frame: Day 9 and Day 10

  6. Area under concentration-time curve in the dosing interval (AUCtau) of AZD4604

    The AUCtau of AZD4604 at Day 10 of dosing with dose A, when delivered by the Genuair device will be characterised.

    Time frame: Day 9 and Day 10

  7. Apparent total body clearance (CL/F) of AZD4604

    The CL/F of AZD4604 at Day 10 of dosing with dose A, when delivered by the Genuair device will be characterised.

    Time frame: Day 10

  8. Apparent volume of distribution based on the terminal phase (VZ/F)

    The VZ/F of AZD4604 at Day 10 of dosing with dose A, when delivered by the Genuair device will be characterised.

    Time frame: Day 10

  9. Dose normalised AUCtau (AUCtau/D) of AZD4604

    The AUCtau/D of AZD4604 at Day 10 of dosing with dose A, when delivered by the Genuair device will be characterised.

    Time frame: Day 9 and Day 10

  10. Dose normalised Cmax (Cmax/D) of AZD4604

    The Cmax/D of AZD4604 at Day 10 of dosing with dose A, when delivered by the Genuair device will be characterised.

    Time frame: Day 9 and Day 10

  11. Maximum observed drug concentration (Cmax) of AZD4604

    The Cmax of AZD4604 at Day 10 of dosing with dose A is compared via the Turbuhaler and Genuair devices.

    Time frame: Day 9 and Day 10

  12. Area under concentration-time curve in the dosing interval (AUCtau)

    The AUCtau of AZD4604 at Day 10 of dosing with dose A is compared via the Turbuhaler and Genuair devices.

    Time frame: Day 9 and Day 10

07

Study locations

10 sites
  • Research Site
    Berlin, 10119, Germany
  • Research Site
    Berlin, 10787, Germany
  • Research Site
    Frankfurt, 60596, Germany
  • Research Site
    Großhansdorf, 22927, Germany
  • Research Site
    Lübeck, 23552, Germany
  • Research Site
    Cambridge, CB2 0AY, United Kingdom
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
  • Research Site
    Liverpool, L7 8XP, United Kingdom
  • Research Site
    London, N12 8BU, United Kingdom
  • Research Site
    Wythenshawe, M23 9QZ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in May 2025, 3 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 13, 2024
StartActual
Feb 27, 2025
Primary completionActual
May 29, 2025
CompletionActual
May 29, 2025
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06732882
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Feb 27, 2025
Primary completion
May 29, 2025
Completion
May 29, 2025
Last update
Jun 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Londamocitinib

Start the discussion